Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
Clinical trial NCT00310804 · COMPLETED
Trial details
- NCT number
- NCT00310804
- Sponsor
- Novartis Vaccines
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2005-09-01
- Primary completion
- 2005-10-01
- Enrollment
- 1200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.